Standpoint Research Starts Kite Pharma (KITE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Standpoint Research Starts Kite Pharma (KITE) at Buy
August 17, 2015 11:13 AM EDT
Stifel analyst Thomas Shrader reiterated a Buy rating and $83 price target on Kite Pharma (NASDAQ: KITE) after the company confirmed a patient died after receiving KTE019 treatment in the Phase I portion of the ongoing DLBCL trial. The death was ruled not related to KTE019 by the investigator.... More
August 17, 2015 8:55 AM EDT
Mizuho Securities analyst Peter Lawson reiterated his Outperform rating and $90 price target on Kite Pharma (NASDAQ: KITE) after the company announced it will host a conference call to discuss KTE-C19 Phase 1 data with news that the patient death is untreated to the drug.
Lawson commented, "KITE will host a conference call today at... More
August 17, 2015 8:01 AM EDT
Kite Pharma, Inc. (Kite) (Nasdaq: KITE) today provided an update from the Company's ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma (NHL) who have failed prior chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.
In May, Kite announced that the first patient was treated with KTE-C19 in... More
